Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant? - Wikidata - wikimedia - TriplyDB

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

http://www.wikidata.org/entity/Q53525858

about

Prevalence of Anxiety among Hungarian Subjects with Parkinson's Disease.Minimal clinically important difference of voice handicap index-10 in vocal fold paralysis.Autonomic dysfunction in Parkinson's disease: A prospective cohort study.Objective measurement in routine care of people with Parkinson's disease improves outcomes.

P2860

Q42706737-411B34C9-0C1B-43D3-8A13-1C0355B6C47F Q47793885-23625CB5-5481-4902-928B-9D047807758A Q48348979-22E31212-DC0E-40F0-B2B2-025212403C70 Q55219011-7BE8AC50-9718-4FDE-96C2-CC791AF3E837

P2860

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

http://www.wikidata.org/entity/Q53525858

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@en

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@nl

type

label

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@en

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@nl

prefLabel

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@en

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@nl

P1433

Q53525858-4E4C0D19-4905-4E36-BCFE-A6D8E9CA3543

P1476

Q53525858-1B92B0D8-11C5-44AE-9DEC-9278D4A9B157

P2093

Q53525858-22BCA47C-1DA4-4AFF-B40F-DAAFF4C0B545

Q53525858-31BF1D95-F68A-47EA-9A5C-F4241F3DFFA7

Q53525858-3BB93C43-EFB5-4751-A446-1EA8C56EDCE5

Q53525858-5139A021-3C18-4CEA-83D7-E310E19AAA49

Q53525858-54954748-1437-4FE5-8C43-EECEA8F47077

Q53525858-74AE4032-C15D-4548-9BCE-474E70953A9D

Q53525858-82BAC545-D474-4F96-805B-74CEFAD66CF7

Q53525858-9D725FD6-D0DF-4485-8531-BF86E7E49DA3

Q53525858-DE0BA6A0-D3B0-4608-A9E5-9E731487B3DC

P2860

Q53525858-0949EF12-FBCE-4574-8A99-8797EF2924B7

Q53525858-26B6E5B1-4108-4795-A48C-C15BCAA1916D

Q53525858-2E50E37B-3C40-4087-BE4D-C8622090CB18

Q53525858-2E6E879B-E72A-4C51-8258-9F2ABB147DA5

Q53525858-31F18F7C-FED5-41E3-A3F6-D529B5DF8CD6

Q53525858-8209370B-4FDA-4B5B-828E-A37243D50851

Q53525858-93B33EF3-B149-452A-8356-14143CF4EB8A

Q53525858-9CA6AD88-5A1E-4C92-A7D4-7DFDDAFD7CCB

Q53525858-9E106C32-2898-4523-8EA0-DC5158B1E255

Q53525858-A3DCF20E-966A-4E89-B17E-8CDC6C6474E5

P304

Q53525858-8210057B-F18C-45EE-A1FD-B0DECA5B6D9D

P31

Q53525858-24A2CADE-2C13-49EA-8135-C61538F4A4F2

P356

Q53525858-1BFD6C76-2BAD-4767-94B4-C898C5B363D1

P433

Q53525858-BB3F70C7-BB75-4919-8B8D-1F0240F17375

P478

Q53525858-B6E1A9DA-4C01-4EEA-8BF4-B57F65A515FD

P577

Q53525858-886561CA-DD91-4BB4-B26B-A3817122B6E7

P698

Q53525858-B2676A4C-D98E-4496-8757-5FF4B36819CE

P921

Q53525858-92231713-7A3F-4459-BD83-3177B6F32C79

Q53525858-9A78902F-DDC8-412B-A435-A78079E9C4BF

P356

P1433

Neuroepidemiology

P1476

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

@en

P2093

Attila Makkos

http://www.w3.org/2001/XMLSchema#string

József Janszky

http://www.w3.org/2001/XMLSchema#string

Krisztina Horváth

http://www.w3.org/2001/XMLSchema#string

Kázmér Karádi

http://www.w3.org/2001/XMLSchema#string

Márk Harmat

http://www.w3.org/2001/XMLSchema#string

Márton Kovács

http://www.w3.org/2001/XMLSchema#string

Norbert Kovács

http://www.w3.org/2001/XMLSchema#string

Sámuel Komoly

http://www.w3.org/2001/XMLSchema#string

Zsuzsanna Aschermann

http://www.w3.org/2001/XMLSchema#string

P2860

Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

The 39-Item Parkinson's Disease Questionnaire (PDQ-39): Is it a Unidimensional Construct?

Measurement of health status. Ascertaining the minimal clinically important difference.

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.

Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release

Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.

Comparing results from long and short form versions of the Parkinson's disease questionnaire in a longitudinal study.

Determination of minimal clinically important change in early and advanced Parkinson's disease.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000455863

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28161701

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

quality of life